Vertex Pharmaceuticals Incorporated
521.12USD
-7.7800 (-1.47%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,334 | 2,987 | 3,190 | 3,076 | 2,965 | 2,770 | 2,912 | 2,772 |
| Cost of Revenue | 489 | 393 | 466 | 415 | 408 | 363 | 423 | 393 |
| Gross Profit | 2,845 | 2,594 | 2,724 | 2,662 | 2,557 | 2,407 | 2,489 | 2,379 |
| Operating Income | 1,247 | 1,138 | 1,206 | 1,186 | 1,151 | 630 | 1,026 | 1,116 |
| Net Income | 1,100 | 1,031 | 1,191 | 1,083 | 1,033 | 646 | 913 | 1,045 |
| EPS (Diluted) | $4.31 | $4.02 | $4.64 | $4.20 | $3.99 | $2.49 | $3.53 | $4.01 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)